HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Jerome Ritz Selected Research

Interferon-gamma (Interferon, gamma)

6/2015Interferon-γ-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression.
5/2010Clearance of CMV viremia and survival after double umbilical cord blood transplantation in adults depends on reconstitution of thymopoiesis.
2/2002Synergistic enhancement of cell-mediated immunity by interleukin-12 plus interleukin-2: basis for therapy of cutaneous T cell lymphoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Jerome Ritz Research Topics

Disease

54Neoplasms (Cancer)
01/2022 - 05/2002
47Bronchiolitis Obliterans Syndrome
11/2022 - 04/2004
33Graft vs Host Disease (Graft-Versus-Host Disease)
12/2022 - 09/2002
29Leukemia
12/2022 - 06/2002
20Hematologic Neoplasms (Hematological Malignancy)
01/2022 - 10/2003
12Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
01/2022 - 10/2006
11BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
02/2014 - 05/2002
10Multiple Myeloma
12/2020 - 06/2002
9Myelodysplastic Syndromes (Myelodysplastic Syndrome)
10/2022 - 10/2006
8B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
01/2020 - 12/2005
5Disease Progression
01/2021 - 03/2011
5Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
01/2020 - 06/2005
4Lymphoma (Lymphomas)
01/2022 - 12/2016
4Infections
01/2022 - 04/2012
4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL)
01/2020 - 04/2004
4Melanoma (Melanoma, Malignant)
01/2018 - 05/2002
3Bronchiolitis Obliterans
12/2022 - 02/2012
3Viremia
01/2022 - 05/2010
3Hodgkin Disease (Hodgkin's Disease)
01/2022 - 05/2017
3Virus Diseases (Viral Diseases)
01/2021 - 01/2020
3Non-Hodgkin Lymphoma (Lymphosarcoma)
01/2020 - 06/2002
3B-Cell Lymphoma (Lymphoma, B Cell)
01/2019 - 01/2016
2Injection Site Reaction
12/2022 - 11/2017
2Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse)
01/2022 - 01/2020
2Anemia
11/2021 - 01/2021
2Systemic Lupus Erythematosus (Libman-Sacks Disease)
01/2021 - 01/2016
2COVID-19
01/2021 - 07/2020
2Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
01/2017 - 05/2002
2Fibrosis (Cirrhosis)
01/2017 - 02/2012
2Myeloid Leukemia (Leukemia, Myelocytic)
03/2015 - 02/2010
2Renal Cell Carcinoma (Grawitz Tumor)
02/2009 - 08/2008
2Blast Crisis (Blast Phase)
08/2004 - 12/2002
1Immune System Diseases (Immune Disorders)
01/2022
1Chronic Renal Insufficiency
01/2021

Drug/Important Bio-Agent (IBA)

20AntigensIBA
01/2021 - 05/2002
15Interleukin-2 (IL2)IBA
11/2022 - 02/2002
12VaccinesIBA
12/2022 - 05/2002
11AntibodiesIBA
01/2018 - 05/2002
10Proteins (Proteins, Gene)FDA Link
01/2017 - 01/2004
8Tacrolimus (Prograf)FDA LinkGeneric
12/2022 - 10/2009
8Minor Histocompatibility AntigensIBA
03/2010 - 01/2003
7Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA
12/2022 - 05/2002
6Methotrexate (Mexate)FDA LinkGeneric
12/2022 - 10/2009
6SteroidsIBA
11/2022 - 08/2004
5CytokinesIBA
01/2022 - 02/2002
5Biomarkers (Surrogate Marker)IBA
01/2020 - 08/2013
5Bortezomib (Velcade)FDA Link
01/2018 - 10/2009
5Peptides (Polypeptides)IBA
01/2017 - 01/2004
5Complementary DNA (cDNA)IBA
03/2015 - 05/2002
4Sirolimus (Rapamycin)FDA Link
01/2020 - 01/2018
4Biological ProductsIBA
11/2017 - 06/2005
4Immunoglobulins (Immunoglobulin)IBA
06/2014 - 02/2010
4Rituximab (Mabthera)FDA Link
06/2013 - 06/2002
3Cell-Free Nucleic AcidsIBA
01/2022 - 07/2020
3InterferonsIBA
12/2020 - 06/2015
3Pharmaceutical PreparationsIBA
12/2020 - 11/2016
3LigandsIBA
01/2020 - 06/2015
3EpitopesIBA
01/2019 - 01/2004
3Immune Checkpoint InhibitorsIBA
01/2018 - 07/2016
3Monoclonal AntibodiesIBA
01/2017 - 10/2002
3Interferon-gamma (Interferon, gamma)IBA
06/2015 - 02/2002
3B-Cell Activating FactorIBA
05/2014 - 10/2007
2pembrolizumabIBA
01/2022 - 01/2019
2Interleukin-22 (IL-22)IBA
11/2021 - 01/2021
2IpilimumabIBA
10/2021 - 07/2016
2Chimeric Antigen ReceptorsIBA
01/2020 - 01/2018
2Antilymphocyte Serum (Anti-Thymocyte Globulin)IBA
01/2020 - 12/2017
2Transcription Factors (Transcription Factor)IBA
01/2019 - 01/2019
2Thomsen-Friedenreich antibodiesIBA
11/2018 - 12/2017
2GlobulinsIBA
11/2018 - 12/2017
2T-Cell Antigen Receptors (T-Cell Receptor)IBA
04/2018 - 05/2010
2Cyclophosphamide (Cytoxan)FDA LinkGeneric
01/2018 - 02/2012
2HLA Antigens (Human Leukocyte Antigens)IBA
01/2018 - 07/2006
2Programmed Cell Death 1 ReceptorIBA
01/2018 - 01/2017
2DNA (Deoxyribonucleic Acid)IBA
12/2016 - 05/2010
2Busulfan (Busulfex)FDA Link
11/2015 - 06/2010
2fludarabineIBA
11/2015 - 06/2010
2Interleukin-2 Receptors (IL 2 Receptor)IBA
10/2014 - 11/2009
2Alemtuzumab (Campath)FDA Link
06/2013 - 05/2013
2Nucleic AcidsIBA
04/2011 - 02/2009
2Staphylococcal Protein A (Protein A)IBA
02/2009 - 01/2008
2OligonucleotidesIBA
05/2007 - 01/2006
2AutoantibodiesIBA
03/2007 - 10/2002
2Imatinib Mesylate (Gleevec)FDA Link
08/2004 - 01/2004
1ChromatinIBA
12/2022
1Enzyme Inhibitors (Inhibitors, Enzyme)IBA
12/2022
1CalcineurinIBA
10/2022
1RNA (Ribonucleic Acid)IBA
01/2022

Therapy/Procedure

57Hematopoietic Stem Cell Transplantation
11/2022 - 10/2002
37Therapeutics
01/2022 - 02/2002
21Transplantation
10/2021 - 06/2002
17Stem Cell Transplantation
01/2022 - 09/2002
13Cell Transplantation
10/2022 - 10/2006
11Immunotherapy
01/2022 - 06/2002
6Drug Therapy (Chemotherapy)
01/2022 - 10/2006
5Bone Marrow Transplantation (Transplantation, Bone Marrow)
01/2016 - 07/2002
4Homologous Transplantation
11/2020 - 08/2004
2Aftercare (After-Treatment)
11/2021 - 02/2010
2Cell- and Tissue-Based Therapy (Cell Therapy)
11/2021 - 01/2018
1Duration of Therapy
01/2021